The present disclosure relates to use of single vision ophthalmic lenses for correction of myopia in a wearer, wherein the single vision ophthalmic lens devices are configured with a base prescription to correct the myopia of the individual and are purposefully further configured with non-refractive features, wherein the non-refractive features facilitate an increase in the retinal ganglion cell activity for the wearer, which may serve as an optical stop signal to decelerate, ameliorate, control, inhibit, or reduce, the rate of myopia progression of the wearer.